1093 CLN-617 combines IL-2 and IL-12 in a single molecule to optimally balance safety and efficacy upon intratumoral injection

Eitemau Tebyg

• 194 Characterization of the pharmacodynamic activity of CLN-619, an anti-MICA/B monoclonal antibody, in patients from an ongoing Phase 1 trial
  gan: Victor Moreno, et al.
  Cyhoeddwyd: (2023-11-01)
• 1093 CLN-617 combines IL-2 and IL-12 in a single molecule to optimally balance safety and efficacy upon intratumoral injection
  gan: Naveen K Mehta, et al.
  Cyhoeddwyd: (2023-11-01)
• 1024 CLN-978, a novel CD19/CD3/HSA T cell engager with extended serum half-life, is effective against lymphoma cells expressing very low levels of CD19
  gan: Agapitos Patakas, et al.
  Cyhoeddwyd: (2023-11-01)
• Engaging natural killer cells for cancer therapy via NKG2D, CD16A and other receptors
  gan: Kerry A. Whalen, et al.
  Cyhoeddwyd: (2023-12-01)
• CLN-978, a novel half-life extended CD19/CD3/HSA-specific T cell-engaging antibody construct with potent activity against B-cell malignancies with low CD19 expression
  gan: Agapitos Patakas, et al.
  Cyhoeddwyd: (2023-08-01)